Compare Sun Pharma with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs CADILA HEALTHCARE - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA CADILA HEALTHCARE SUN PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 27.4 30.2 90.8% View Chart
P/BV x 2.8 3.6 76.8% View Chart
Dividend Yield % 0.6 1.0 60.3%  

Financials

 SUN PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
CADILA HEALTHCARE
Mar-19
SUN PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs679432 157.0%   
Low Rs375306 122.5%   
Sales per share (Unadj.) Rs121.1128.6 94.2%  
Earnings per share (Unadj.) Rs13.418.5 72.1%  
Cash flow per share (Unadj.) Rs20.724.4 84.8%  
Dividends per share (Unadj.) Rs2.753.50 78.6%  
Dividend yield (eoy) %0.50.9 55.1%  
Book value per share (Unadj.) Rs172.6101.5 170.1%  
Shares outstanding (eoy) m2,399.261,023.74 234.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.42.9 151.5%   
Avg P/E ratio x39.419.9 197.8%  
P/CF ratio (eoy) x25.515.1 168.3%  
Price / Book Value ratio x3.13.6 83.9%  
Dividend payout %20.618.9 108.9%   
Avg Mkt Cap Rs m1,264,650378,170 334.4%   
No. of employees `00017.512.4 140.7%   
Total wages/salary Rs m59,67121,241 280.9%   
Avg. sales/employee Rs Th16,608.110,585.0 156.9%   
Avg. wages/employee Rs Th3,409.61,707.8 199.7%   
Avg. net profit/employee Rs Th1,833.81,526.5 120.1%   
INCOME DATA
Net Sales Rs m290,659131,656 220.8%  
Other income Rs m10,2552,011 509.9%   
Total revenues Rs m300,914133,667 225.1%   
Gross profit Rs m63,07629,731 212.2%  
Depreciation Rs m17,5335,986 292.9%   
Interest Rs m5,5531,935 287.0%   
Profit before tax Rs m50,24623,821 210.9%   
Minority Interest Rs m0469 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,1440-   
Tax Rs m6,0095,303 113.3%   
Profit after tax Rs m32,09318,987 169.0%  
Gross profit margin %21.722.6 96.1%  
Effective tax rate %12.022.3 53.7%   
Net profit margin %11.014.4 76.6%  
BALANCE SHEET DATA
Current assets Rs m310,69284,981 365.6%   
Current liabilities Rs m173,39673,425 236.2%   
Net working cap to sales %47.28.8 538.2%  
Current ratio x1.81.2 154.8%  
Inventory Days Days9975 132.9%  
Debtors Days Days112110 101.9%  
Net fixed assets Rs m232,477133,493 174.1%   
Share capital Rs m2,3991,024 234.3%   
"Free" reserves Rs m411,691102,839 400.3%   
Net worth Rs m414,091103,863 398.7%   
Long term debt Rs m15,22639,497 38.6%   
Total assets Rs m646,938234,831 275.5%  
Interest coverage x10.013.3 75.5%   
Debt to equity ratio x00.4 9.7%  
Sales to assets ratio x0.40.6 80.1%   
Return on assets %5.88.9 65.3%  
Return on equity %7.818.3 42.4%  
Return on capital %10.218.3 55.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m66,02548,404 136.4%   
Fx outflow Rs m38,61011,593 333.0%   
Net fx Rs m27,41536,811 74.5%   
CASH FLOW
From Operations Rs m21,96528,823 76.2%  
From Investments Rs m-6,813-57,387 11.9%  
From Financial Activity Rs m-27,30518,846 -144.9%  
Net Cashflow Rs m-8,442-7,105 118.8%  

Share Holding

Indian Promoters % 63.7 74.8 85.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 8.3 61.8%  
FIIs % 23.0 5.9 389.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 11.0 75.5%  
Shareholders   133,026 44,069 301.9%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 178 Points Higher; Telecom and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest throughout the day today and ended on a positive note.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jul 3, 2020 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS